-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer is the most common cancer among women.
According to the 2021 Cancer Statistics Report of Divine Magazine, breast cancer has become the first of the three major cancers in women, and breast cancer alone accounts for 30% of female cancers
.
In China, the incidence of breast cancer is also increasing year by year
Breast cancer is the most common cancer among women.
Triple-negative breast cancer accounts for 10-15% of breast cancers, and local recurrence and metastasis occur in about half of patients regardless of treatment
.
There is currently no specific treatment to prevent recurrence and metastasis
As early as 2014, researchers at the Institute of Experimental and Clinical Research at the University of Leuven (UC Louvain) in Belgium successfully demonstrated the principle of preventing the emergence of melanoma tumor metastasis in mice
.
However, the experimental molecules used at the time were far from drugs
Since then, the researchers have further succeeded in identifying a drug, MitoQ, that prevents breast cancer metastasis in 80% of mice and local recurrence in 75% of mice
.
In contrast, most of the untreated mice developed cancer recurrence and spread
On March 15, 2022, researchers from the University of Leuven (UC Louvain) in Belgium published the study under the title " MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice " in the journal Cancers
.
The study showed that a new drug, MitoQ, was more effective in preventing breast cancer recurrence and metastasis, preventing 80% of breast cancer metastasis in mice and 75% of local recurrence
.
In the study, the researchers created a mouse model of human breast cancer and treated the mice by combining surgical intervention with chemotherapy, adding the new molecule MitoQ to the treatment
.
The study showed that MitoQ was not only compatible with chemotherapy, but that this innovative therapy also prevented the recurrence and metastasis of breast cancer in mice
.
Avoiding cancer recurrence was completely unexpected, the researchers said
.
The three main causes of cancer death are recurrence, cancer generalization due to metastasis, and resistance to therapy
MitoQ inhibits the metastasis of triple-negative breast cancer in mice
MitoQ inhibits the metastasis of triple- negative breast cancer in mice MitoQ inhibits the metastasis of triple-negative breast cancer in miceIt is reported that MitoQ has successfully passed the first clinical stage, it has been tested in healthy patients, the results show that it has only mild side effects (nausea, vomiting)
The findings from this study open the door to a Phase 2 clinical trial aimed at demonstrating the efficacy of new treatments in cancer patients, with Phase 2 and Phase 3 testing soon
Original source:
Original source:Tania Capeloa, et al.
MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice Leave a Comment
